title: Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride.
abstract: To control the minimum effective dose, and reduce the number and quantity of administered potent drugs are unique features of advanced drug delivery in situ forming gel formulation. The efficacy, consistency, and increasing the application of existing injection therapies can be enhanced through optimization of controlled released systems by using FDA approved biodegradable PLGA (poly-d,l-lactide-co-glycolide) polymer. The purpose of this study was to develop different in situ forming implant (ISFI) formulations of buprenorphine hydrochloride for post treatment of drug addicts, acute and chronic pains. The drug releases from different ISFIs membranes with and without Tween 80 were compared over a period of time. Kinetic equation followed the Korsmeyer-Peppas model, as the plots showed high linearity. The influence of this additive on polymer properties was investigated using differential scanning calorimetry (DSC), and the membranes structure was studied by X-ray diffractometry (XRD) and scanning electron microscope (SEM). Data revealed that Tween 80 modified the drug release pattern using diffusion mechanism and decreased the glass transition temperature (T g) significantly. The degree of crystallinity was decreased after phase inversion which helps the dissolution of drug from membrane. The porosity of modified membranes was in accordance with release profiles. These findings suggest four different in situ forming implant formulations which can release various dose of the buprenorphine hydrochloride in a prolonged time. Also this surfactant can be an attractive additive for modifying the release rate of drugs from PLGA-based membrane drug delivery systems.
authors: Membrane Research Center, Chemical Engineering Department, Razi University, Kermanshah, Iran.
authors: S
authors: S
authors: Koocheki
authors: S S
authors: SS
authors: Madaeni
authors: P
authors: P
authors: Niroomandi
keywords: Buprenorphine HCl; In situ forming implant; Membrane; PLGA; Tween 80
references: J Control Release. 1999 Dec 6;62(3):333-44
references: 10528071
references: J Pharm Sci. 2000 Jun;89(6):732-41
references: 10824131
references: J Pain Symptom Manage. 2005 Mar;29(3):297-326
references: 15781180
references: Eur J Pharm Sci. 2009 Sep 10;38(2):138-46
references: 19591929
references: Addict Behav. 2007 Feb;32(2):320-31
references: 16814937
references: Neurotoxicol Teratol. 1995 Jul-Aug;17(4):419-23
references: 7565488
references: Nanomedicine. 2009 Mar;5(1):90-5
references: 18823824
references: Eur J Pharm Sci. 2002 Jul;16(1-2):53-61
references: 12113891
references: AAPS PharmSciTech. 2007 Aug 03;8(3):E62
references: 17915812
references: Nanomedicine. 2010 Apr;6(2):324-33
references: 19857606
references: J Control Release. 2008 Sep 24;130(3):220-5
references: 18611421
references: Saudi Pharm J. 2011 Jan;19(1):19-27
references: 24115901
references: J Control Release. 2005 Nov 2;108(1):1-9
references: 16098624
references: Pak J Pharm Sci. 2006 Apr;19(2):119-24
references: 16751122
references: Eur J Pharm Biopharm. 2004 Sep;58(2):445-55
references: 15296966
references: J Colloid Interface Sci. 2009 Feb 15;330(2):443-8
references: 19038395
references: AAPS J. 2007 Oct 26;9(3):E344-52
references: 18170981
references: Molecules. 2009 Sep 01;14(9):3286-312
references: 19783926
references: Curr Drug Deliv. 2009 Apr;6(2):184-91
references: 19450225
references: J Control Release. 2006 Jan 10;110(2):266-272
references: 16300851
references: Drug Alcohol Depend. 1999 Aug 2;56(1):55-60
references: 10462093
references: Drug Dev Ind Pharm. 2009 Feb;35(2):185-91
references: 18825525